Business Description
China SXT Pharmaceuticals Inc
ISIN : VGG2161P1403
Share Class Description:
STU:2RY0: Ordinary SharesDescription
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.56 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -1.13 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -1.36 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -76.2 | |||||
| 3-Year EBITDA Growth Rate | 65.1 | |||||
| 3-Year EPS without NRI Growth Rate | 66.6 | |||||
| 3-Year FCF Growth Rate | 64.2 | |||||
| 3-Year Book Growth Rate | -77 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.14 | |||||
| 9-Day RSI | 43.74 | |||||
| 14-Day RSI | 44.27 | |||||
| 6-1 Month Momentum % | -40.23 | |||||
| 12-1 Month Momentum % | 413.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | |||||
| Quick Ratio | 1.51 | |||||
| Cash Ratio | 1.36 | |||||
| Days Inventory | 160.95 | |||||
| Days Sales Outstanding | 250.46 | |||||
| Days Payable | 351.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -314.9 | |||||
| Shareholder Yield % | -19.68 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 28.72 | |||||
| Operating Margin % | -130.38 | |||||
| Net Margin % | -160.6 | |||||
| FCF Margin % | -99.55 | |||||
| ROE % | -27.58 | |||||
| ROA % | -13.82 | |||||
| ROIC % | -23.77 | |||||
| 3-Year ROIIC % | 51.81 | |||||
| ROC (Joel Greenblatt) % | -264.04 | |||||
| ROCE % | -22.11 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.23 | |||||
| PB Ratio | 0.1 | |||||
| Price-to-Tangible-Book | 0.09 | |||||
| EV-to-EBIT | 2.87 | |||||
| EV-to-EBITDA | 3.11 | |||||
| EV-to-Revenue | -3.8 | |||||
| EV-to-FCF | 3.79 | |||||
| Price-to-Projected-FCF | 0.06 | |||||
| Price-to-Net-Current-Asset-Value | 0.26 | |||||
| Price-to-Net-Cash | 0.45 | |||||
| Earnings Yield (Greenblatt) % | 34.82 | |||||
| FCF Yield % | -91.51 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers